marked.bio

Company

Jiangsu Alphamab Biopharmaceuticals

3 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

JSKN003 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 4 trials shown

  1. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

    Recruiting Phase 3 Jiangsu Alphamab Biopharmaceuticals Started 2023Primary completion 2026-04 NCT06079983

    JSKN003capecitabinegemcitabinevinorelbinepaclitaxeldocetaxeleribulin

    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer

  2. A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

    Not yet recruiting Phase 2 Jiangsu Alphamab Biopharmaceuticals Started 2025Primary completion 2027-08 NCT07283198

    JSKN033 Injection

    …astatic NSCLC who have failed or are intolerant to standard previous treatments, and have HER2 mutation or HER2 expression in tumor tissue.

    HER2 (ERBB2) activating mutationNon Small Cell Lung Cancer (NSCLC)

  3. To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

    Recruiting Phase 1 Jiangsu Alphamab Biopharmaceuticals Started 2024Primary completion 2026-05 NCT06592417

    JSKN016 injection

    EGFR, ALK, ROS1, NTRK, BRAF V600, MET exon 14, RET, KRAS G12C, or HER2;

    KRAS G12CBRAF V600EMET exon 14 skippingStatus may be outdated, last updated 2024-09-19Advanced Malignant Solid Tumor